25 XP   0   0   10

Gracell Biotechnologies Inc.
Buy, Hold or Sell?

Let's analyse Gracell Biotechnologies Inc. together

PenkeI guess you are interested in Gracell Biotechnologies Inc.. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Gracell Biotechnologies Inc.. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Gracell Biotechnologies Inc.

I send you an email if I find something interesting about Gracell Biotechnologies Inc..

Quick analysis of Gracell Biotechnologies Inc. (30 sec.)










What can you expect buying and holding a share of Gracell Biotechnologies Inc.? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.77
Expected worth in 1 year
$-1.62
How sure are you?
80.0%

+ What do you gain per year?

Total Gains per Share
$-3.38
Return On Investment
-33.0%

For what price can you sell your share?

Current Price per Share
$10.25
Expected price per share
$6.99 - $10.44
How sure are you?
50%

1. Valuation of Gracell Biotechnologies Inc. (5 min.)




Live pricePrice per Share (EOD)

$10.25

Intrinsic Value Per Share

$-8.95 - $-10.64

Total Value Per Share

$-7.18 - $-8.87

2. Growth of Gracell Biotechnologies Inc. (5 min.)




Is Gracell Biotechnologies Inc. growing?

Current yearPrevious yearGrowGrow %
How rich?$190.1m$252.5m-$62.4m-32.8%

How much money is Gracell Biotechnologies Inc. making?

Current yearPrevious yearGrowGrow %
Making money-$83.9m-$64.3m-$19.5m-23.3%
Net Profit Margin0.0%-127,289.6%--

How much money comes from the company's main activities?

3. Financial Health of Gracell Biotechnologies Inc. (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#266 / 1019

Most Revenue
#969 / 1019

Most Profit
#960 / 1019

Most Efficient
#420 / 1019

What can you expect buying and holding a share of Gracell Biotechnologies Inc.? (5 min.)

Welcome investor! Gracell Biotechnologies Inc.'s management wants to use your money to grow the business. In return you get a share of Gracell Biotechnologies Inc..

What can you expect buying and holding a share of Gracell Biotechnologies Inc.?

First you should know what it really means to hold a share of Gracell Biotechnologies Inc.. And how you can make/lose money.

Speculation

The Price per Share of Gracell Biotechnologies Inc. is $10.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Gracell Biotechnologies Inc..
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Gracell Biotechnologies Inc., you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.77. Based on the TTM, the Book Value Change Per Share is $-0.85 per quarter. Based on the YOY, the Book Value Change Per Share is $1.44 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Gracell Biotechnologies Inc..

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.78-7.6%-0.78-7.6%-0.65-6.3%-0.44-4.3%-0.44-4.3%
Usd Book Value Change Per Share-0.85-8.3%-0.85-8.3%1.4414.1%0.353.5%0.353.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.85-8.3%-0.85-8.3%1.4414.1%0.353.5%0.353.5%
Usd Price Per Share2.30-2.30-6.04-1.67-1.67-
Price to Earnings Ratio-2.94--2.94--9.30--2.45--2.45-
Price-to-Total Gains Ratio-2.72--2.72-4.19-0.74-0.74-
Price to Book Ratio1.30-1.30-2.31-0.72-0.72-
Price-to-Total Gains Ratio-2.72--2.72-4.19-0.74-0.74-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.25
Number of shares97
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.850.35
Usd Total Gains Per Share-0.850.35
Gains per Quarter (97 shares)-82.0834.32
Gains per Year (97 shares)-328.31137.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-328-3380137127
20-657-6660275264
30-985-9940412401
40-1313-13220549538
50-1642-16500686675
60-1970-19780824812
70-2298-23060961949
80-2627-2634010981086
90-2955-2962012351223
100-3283-3290013731360

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.05.00.00.0%0.05.00.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%4.01.00.080.0%4.01.00.080.0%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.05.00.0%0.00.05.00.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%4.01.00.080.0%4.01.00.080.0%4.01.00.080.0%

Fundamentals of Gracell Biotechnologies Inc.

About Gracell Biotechnologies Inc.

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Fundamental data was last updated by Penke on 2024-04-11 10:15:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Gracell Biotechnologies Inc..

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Gracell Biotechnologies Inc. earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Gracell Biotechnologies Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-127,289.6%+127,289.6%
TTM-5Y-25,457.9%+25,457.9%
5Y-25,457.9%10Y-25,457.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--196.9%+196.9%
TTM--211.2%+211.2%
YOY-127,289.6%-279.3%-127,010.3%
5Y-25,457.9%-436.8%-25,021.1%
10Y-25,457.9%-599.3%-24,858.6%
1.1.2. Return on Assets

Shows how efficient Gracell Biotechnologies Inc. is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • -36.7% Return on Assets means that Gracell Biotechnologies Inc. generated $-0.37 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Gracell Biotechnologies Inc.:

  • The MRQ is -36.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -36.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-36.7%TTM-36.7%0.0%
TTM-36.7%YOY-22.6%-14.1%
TTM-36.7%5Y-30.5%-6.1%
5Y-30.5%10Y-30.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.7%-13.6%-23.1%
TTM-36.7%-12.9%-23.8%
YOY-22.6%-11.9%-10.7%
5Y-30.5%-14.2%-16.3%
10Y-30.5%-16.2%-14.3%
1.1.3. Return on Equity

Shows how efficient Gracell Biotechnologies Inc. is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • -44.2% Return on Equity means Gracell Biotechnologies Inc. generated $-0.44 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Gracell Biotechnologies Inc.:

  • The MRQ is -44.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -44.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-44.2%TTM-44.2%0.0%
TTM-44.2%YOY-25.5%-18.7%
TTM-44.2%5Y-539.3%+495.2%
5Y-539.3%10Y-539.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-44.2%-17.0%-27.2%
TTM-44.2%-16.1%-28.1%
YOY-25.5%-15.4%-10.1%
5Y-539.3%-20.0%-519.3%
10Y-539.3%-21.1%-518.2%

1.2. Operating Efficiency of Gracell Biotechnologies Inc..

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Gracell Biotechnologies Inc. is operating .

  • Measures how much profit Gracell Biotechnologies Inc. makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Gracell Biotechnologies Inc.:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-126,659.3%+126,659.3%
TTM-5Y-25,331.9%+25,331.9%
5Y-25,331.9%10Y-25,331.9%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--282.4%+282.4%
TTM--225.8%+225.8%
YOY-126,659.3%-288.4%-126,370.9%
5Y-25,331.9%-475.2%-24,856.7%
10Y-25,331.9%-624.7%-24,707.2%
1.2.2. Operating Ratio

Measures how efficient Gracell Biotechnologies Inc. is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Gracell Biotechnologies Inc.:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY1,267.593-1,267.593
TTM-5Y253.519-253.519
5Y253.51910Y253.5190.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.994-2.994
TTM-3.247-3.247
YOY1,267.5933.766+1,263.827
5Y253.5195.675+247.844
10Y253.5197.857+245.662

1.3. Liquidity of Gracell Biotechnologies Inc..

1.3. Liquidity
1.3.1. Current Ratio

Measures if Gracell Biotechnologies Inc. is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.78 means the company has $6.78 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Gracell Biotechnologies Inc.:

  • The MRQ is 6.779. The company is very able to pay all its short-term debts. +2
  • The TTM is 6.779. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.779TTM6.7790.000
TTM6.779YOY12.152-5.373
TTM6.7795Y12.720-5.941
5Y12.72010Y12.7200.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7793.930+2.849
TTM6.7794.251+2.528
YOY12.1525.436+6.716
5Y12.7206.045+6.675
10Y12.7206.383+6.337
1.3.2. Quick Ratio

Measures if Gracell Biotechnologies Inc. is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • A Quick Ratio of 6.74 means the company can pay off $6.74 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Gracell Biotechnologies Inc.:

  • The MRQ is 6.744. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.744. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.744TTM6.7440.000
TTM6.744YOY12.100-5.355
TTM6.7445Y15.181-8.437
5Y15.18110Y15.1810.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7443.629+3.115
TTM6.7444.065+2.679
YOY12.1005.390+6.710
5Y15.1815.993+9.188
10Y15.1816.277+8.904

1.4. Solvency of Gracell Biotechnologies Inc..

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Gracell Biotechnologies Inc. assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Gracell Biotechnologies Inc. to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.17 means that Gracell Biotechnologies Inc. assets are financed with 16.9% credit (debt) and the remaining percentage (100% - 16.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Gracell Biotechnologies Inc.:

  • The MRQ is 0.169. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.169. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.169TTM0.1690.000
TTM0.169YOY0.113+0.056
TTM0.1695Y0.359-0.190
5Y0.35910Y0.3590.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1690.332-0.163
TTM0.1690.333-0.164
YOY0.1130.268-0.155
5Y0.3590.366-0.007
10Y0.3590.390-0.031
1.4.2. Debt to Equity Ratio

Measures if Gracell Biotechnologies Inc. is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • A Debt to Equity ratio of 20.4% means that company has $0.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Gracell Biotechnologies Inc.:

  • The MRQ is 0.204. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.204. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.204TTM0.2040.000
TTM0.204YOY0.127+0.077
TTM0.2045Y12.489-12.285
5Y12.48910Y12.4890.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2040.380-0.176
TTM0.2040.389-0.185
YOY0.1270.334-0.207
5Y12.4890.432+12.057
10Y12.4890.465+12.024

2. Market Valuation of Gracell Biotechnologies Inc.

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Gracell Biotechnologies Inc. generates.

  • Above 15 is considered overpriced but always compare Gracell Biotechnologies Inc. to the Biotechnology industry mean.
  • A PE ratio of -2.94 means the investor is paying $-2.94 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Gracell Biotechnologies Inc.:

  • The EOD is -13.122. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.945. Based on the earnings, the company is expensive. -2
  • The TTM is -2.945. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.122MRQ-2.945-10.178
MRQ-2.945TTM-2.9450.000
TTM-2.945YOY-9.302+6.357
TTM-2.9455Y-2.449-0.495
5Y-2.44910Y-2.4490.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.122-2.426-10.696
MRQ-2.945-2.552-0.393
TTM-2.945-2.656-0.289
YOY-9.302-4.143-5.159
5Y-2.449-6.252+3.803
10Y-2.449-6.108+3.659
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Gracell Biotechnologies Inc.:

  • The EOD is -15.012. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.369. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -3.369. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-15.012MRQ-3.369-11.644
MRQ-3.369TTM-3.3690.000
TTM-3.369YOY-11.682+8.314
TTM-3.3695Y-3.010-0.358
5Y-3.01010Y-3.0100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-15.012-3.199-11.813
MRQ-3.369-3.259-0.110
TTM-3.369-3.552+0.183
YOY-11.682-5.617-6.065
5Y-3.010-8.326+5.316
10Y-3.010-8.689+5.679
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Gracell Biotechnologies Inc. is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.30 means the investor is paying $1.30 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Gracell Biotechnologies Inc.:

  • The EOD is 5.795. Based on the equity, the company is overpriced. -1
  • The MRQ is 1.300. Based on the equity, the company is underpriced. +1
  • The TTM is 1.300. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD5.795MRQ1.300+4.494
MRQ1.300TTM1.3000.000
TTM1.300YOY2.310-1.009
TTM1.3005Y0.722+0.578
5Y0.72210Y0.7220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.7951.947+3.848
MRQ1.3002.116-0.816
TTM1.3002.095-0.795
YOY2.3102.836-0.526
5Y0.7223.443-2.721
10Y0.7223.791-3.069
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Gracell Biotechnologies Inc..

3.1. Institutions holding Gracell Biotechnologies Inc.

Institutions are holding 63.112% of the shares of Gracell Biotechnologies Inc..

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Temasek Holdings Ltd.9.92920.53899588863-313077-3.1618
2023-12-31Vivo Capital, LLC9.88537.84779546485-1334659-12.2658
2023-12-31Orbimed Advisors, LLC9.63911.8665930872600
2023-12-31Sio Capital Management, LLC5.179111.433650015802920364140.3201
2023-12-31TCG Crossover Management, LLC4.6755.0274514786147589748.567
2023-12-31Baker Bros Advisors LP2.15380.237620800001080000108
2023-12-31Pentwater Capital Management LP1.51290.1645146100014610000
2023-12-31Pivotal bioVenture Partners Investment Advisor LLC1.42383.5019137500000
2023-12-31Adage Capital Partners Gp LLC1.39790.0281135000050000058.8235
2023-12-31Test Hedge Fund Mgmt1.3251.6037127959512795950
2023-12-31Eckert Corp1.32380.6582127845412784540
2023-09-30Schonfeld Strategic Advisors LLC0.78630.01775939321570639.6747
2023-12-31BlackRock Inc0.55910.0001539973-19472-3.4806
2023-12-31Qube Research & Technologies0.53560.010151727451464719590.6738
2023-12-31Bank of America Corp0.53010.000551195351128876885.4135
2023-12-31LMR Partners LLP0.52810.0378510001254855.2599
2023-12-31Sphera Funds Management Ltd.0.52080.8127502936-1028561-67.1605
2023-12-31Mmcap International Inc. Spc0.46720.82914511724511720
2023-12-31Harvest Management LLC0.41423.71494000004000000
2023-12-31Hudson Bay Capital Management LP0.27610.017266667-3733333-93.3333
Total 53.062438.346951243858+5684506+11.1%

3.2. Funds holding Gracell Biotechnologies Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Biotech Growth Ord0.78311.812475630400
2023-09-30Galileo - Biotech Innovation Fund S USD0.29572.961428557300
2023-06-30BSF Global Event Driven Z2 USD0.08230.00897949800
2023-12-31AQR Diversified Arbitrage I0.06890.036966578665780
2024-02-29AZ Fd1 AZ Allc Intl 50%-100% A-AZ Cap0.01040.11571000000
2023-12-31China Universal NASDAQ Bio-Tch ETF(QDII)0.00870.074984057512841.2094
2023-12-31AQR Sustainable Corp Abtg IAU1F USD Acc0.00730.0001701470140
2024-01-31Gabelli Entpr Mergers & Acquisitions Y0.00620.1133600060000
2023-12-31PMC Diversified Equity0.00440.00564255-491-10.3456
2024-01-31Comstock Capital Value A0.00310.4971300030000
2023-12-31Gabelli ABC AAA0.00210.0055200020000
2023-12-31GDL Fund0.00210.011200020000
2023-12-31GF NASDAQ Bio-Tech Idx QDII RMB A0.00140.0674138829426.8739
2023-09-30NT Tax Advantaged BONY EM0.00010.00228700
Total 1.27585.71241232102+93907+7.6%

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Gracell Biotechnologies Inc. compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.846-0.8460%1.442-159%0.354-339%0.354-339%
Book Value Per Share--1.7691.7690%2.615-32%1.185+49%1.185+49%
Current Ratio--6.7796.7790%12.152-44%12.720-47%12.720-47%
Debt To Asset Ratio--0.1690.1690%0.113+50%0.359-53%0.359-53%
Debt To Equity Ratio--0.2040.2040%0.127+60%12.489-98%12.489-98%
Dividend Per Share----0%-0%-0%-0%
Eps---0.781-0.7810%-0.649-17%-0.443-43%-0.443-43%
Free Cash Flow Per Share---0.683-0.6830%-0.517-24%-0.395-42%-0.395-42%
Free Cash Flow To Equity Per Share---0.640-0.6400%1.567-141%0.399-260%0.399-260%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---10.643--------
Intrinsic Value_10Y_min---8.948--------
Intrinsic Value_1Y_max---0.649--------
Intrinsic Value_1Y_min---0.631--------
Intrinsic Value_3Y_max---2.268--------
Intrinsic Value_3Y_min---2.136--------
Intrinsic Value_5Y_max---4.271--------
Intrinsic Value_5Y_min---3.895--------
Market Cap989867100.000+75%247217800.000247217800.0000%583297296.000-58%166103019.200+49%166103019.200+49%
Net Profit Margin----0%-1272.8960%-254.5790%-254.5790%
Operating Margin----0%-1266.5930%-253.3190%-253.3190%
Operating Ratio----0%1267.593-100%253.519-100%253.519-100%
Pb Ratio5.795+78%1.3001.3000%2.310-44%0.722+80%0.722+80%
Pe Ratio-13.122-346%-2.945-2.9450%-9.302+216%-2.449-17%-2.449-17%
Price Per Share10.250+78%2.3002.3000%6.040-62%1.668+38%1.668+38%
Price To Free Cash Flow Ratio-15.012-346%-3.369-3.3690%-11.682+247%-3.010-11%-3.010-11%
Price To Total Gains Ratio-12.113-346%-2.718-2.7180%4.188-165%0.735-470%0.735-470%
Quick Ratio--6.7446.7440%12.100-44%15.181-56%15.181-56%
Return On Assets---0.367-0.3670%-0.226-38%-0.305-17%-0.305-17%
Return On Equity---0.442-0.4420%-0.255-42%-5.393+1121%-5.393+1121%
Total Gains Per Share---0.846-0.8460%1.442-159%0.354-339%0.354-339%
Usd Book Value--190130723.000190130723.0000%252542672.200-25%118314070.320+61%118314070.320+61%
Usd Book Value Change Per Share---0.846-0.8460%1.442-159%0.354-339%0.354-339%
Usd Book Value Per Share--1.7691.7690%2.615-32%1.185+49%1.185+49%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.781-0.7810%-0.649-17%-0.443-43%-0.443-43%
Usd Free Cash Flow---73389175.200-73389175.2000%-49930692.600-32%-39661078.240-46%-39661078.240-46%
Usd Free Cash Flow Per Share---0.683-0.6830%-0.517-24%-0.395-42%-0.395-42%
Usd Free Cash Flow To Equity Per Share---0.640-0.6400%1.567-141%0.399-260%0.399-260%
Usd Market Cap989867100.000+75%247217800.000247217800.0000%583297296.000-58%166103019.200+49%166103019.200+49%
Usd Price Per Share10.250+78%2.3002.3000%6.040-62%1.668+38%1.668+38%
Usd Profit---83957743.800-83957743.8000%-64384616.000-23%-40451665.160-52%-40451665.160-52%
Usd Revenue----0%50581.200-100%10116.240-100%10116.240-100%
Usd Total Gains Per Share---0.846-0.8460%1.442-159%0.354-339%0.354-339%
 EOD+5 -3MRQTTM+0 -0YOY+3 -285Y+12 -1910Y+12 -19

4.2. Fundamental Score

Let's check the fundamental score of Gracell Biotechnologies Inc. based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.122
Price to Book Ratio (EOD)Between0-15.795
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than16.744
Current Ratio (MRQ)Greater than16.779
Debt to Asset Ratio (MRQ)Less than10.169
Debt to Equity Ratio (MRQ)Less than10.204
Return on Equity (MRQ)Greater than0.15-0.442
Return on Assets (MRQ)Greater than0.05-0.367
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Gracell Biotechnologies Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.183
Ma 20Greater thanMa 5010.215
Ma 50Greater thanMa 1009.232
Ma 100Greater thanMa 2006.537
OpenGreater thanClose10.250
Total4/5 (80.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2018-12-312019-12-312020-12-312021-12-312022-12-31
Accumulated Other Comprehensive Income  -4447-437-2,868-3,305-4,702-8,00718,16810,162



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets1,656,276
Total Liabilities280,511
Total Stockholder Equity1,375,765
 As reported
Total Liabilities 280,511
Total Stockholder Equity+ 1,375,765
Total Assets = 1,656,276

Assets

Total Assets1,656,276
Total Current Assets1,495,755
Long-term Assets160,521
Total Current Assets
Cash And Cash Equivalents 1,454,645
Short-term Investments 3,559
Net Receivables 26,330
Inventory -26,330
Other Current Assets 37,551
Total Current Assets  (as reported)1,495,755
Total Current Assets  (calculated)1,495,755
+/-0
Long-term Assets
Property Plant Equipment 144,672
Other Assets 15,849
Long-term Assets  (as reported)160,521
Long-term Assets  (calculated)160,521
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities220,642
Long-term Liabilities59,869
Total Stockholder Equity1,375,765
Total Current Liabilities
Short-term Debt 129,989
Short Long Term Debt 112,444
Other Current Liabilities 87,751
Total Current Liabilities  (as reported)220,642
Total Current Liabilities  (calculated)330,184
+/- 109,542
Long-term Liabilities
Long term Debt 46,505
Capital Lease Obligations 24,030
Other Liabilities 6,879
Long-term Liabilities Other 6,879
Long-term Liabilities  (as reported)59,869
Long-term Liabilities  (calculated)84,293
+/- 24,424
Total Stockholder Equity
Common Stock223
Retained Earnings -1,625,281
Accumulated Other Comprehensive Income 73,528
Other Stockholders Equity 2,927,295
Total Stockholder Equity (as reported)1,375,765
Total Stockholder Equity (calculated)1,375,765
+/-0
Other
Capital Stock223
Cash and Short Term Investments 1,458,204
Common Stock Shares Outstanding 107,486
Current Deferred Revenue2,902
Liabilities and Stockholders Equity 1,656,276
Net Debt -1,271,666
Net Invested Capital 1,534,714
Net Tangible Assets 1,375,765
Net Working Capital 1,275,113
Property Plant and Equipment Gross 144,672
Short Long Term Debt Total 182,979



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-31
> Total Assets 
148,518
412,217
964,950
2,060,137
1,656,276
1,656,2762,060,137964,950412,217148,518
   > Total Current Assets 
127,962
340,353
815,469
1,885,080
1,495,755
1,495,7551,885,080815,469340,353127,962
       Cash And Cash Equivalents 
11,890
312,058
754,308
1,829,006
1,454,645
1,454,6451,829,006754,308312,05811,890
       Short-term Investments 
102,000
4,200
18,743
3,615
3,559
3,5593,61518,7434,200102,000
       Net Receivables 
6,200
13,770
30,961
40,690
26,330
26,33040,69030,96113,7706,200
       Inventory 
7,702
9,386
-30,961
8,697
-26,330
-26,3308,697-30,9619,3867,702
       Other Current Assets 
170
939
42,418
3,072
37,551
37,5513,07242,418939170
   > Long-term Assets 
20,556
71,864
149,481
175,057
160,521
160,521175,057149,48171,86420,556
       Property Plant Equipment 
20,556
71,864
119,083
173,438
144,672
144,672173,438119,08371,86420,556
       Long-term Assets Other 
0
0
30,398
1,619
15,849
15,8491,61930,39800
> Total Liabilities 
146,135
156,861
145,287
232,766
280,511
280,511232,766145,287156,861146,135
   > Total Current Liabilities 
7,440
18,166
93,361
155,123
220,642
220,642155,12393,36118,1667,440
       Short-term Debt 
0
0
50,960
86,003
129,989
129,98986,00350,96000
       Short Long Term Debt 
0
0
50,960
68,476
112,444
112,44468,47650,96000
       Accounts payable 
0
0
0
62,459
0
062,459000
       Other Current Liabilities 
7,440
18,166
42,401
3,759
87,751
87,7513,75942,40118,1667,440
   > Long-term Liabilities 
138,695
138,695
51,926
77,643
59,869
59,86977,64351,926138,695138,695
       Long term Debt 
138,695
138,695
51,926
54,349
46,505
46,50554,34951,926138,695138,695
       Other Liabilities 
0
0
0
8,464
6,879
6,8798,464000
       Long-term Liabilities Other 
0
0
0
8,464
6,879
6,8798,464000
> Total Stockholder Equity
2,383
255,356
819,663
1,827,371
1,375,765
1,375,7651,827,371819,663255,3562,383
   Common Stock
69
68
68
223
223
223223686869
   Retained Earnings -1,625,281-1,017,772-564,029-289,396-81,090
   Accumulated Other Comprehensive Income 
-3,212
-3,159
-23,912
-57,936
73,528
73,528-57,936-23,912-3,159-3,212
   Capital Surplus 00000
   Treasury Stock00000
   Other Stockholders Equity 
86,616
553,020
1,383,624
2,902,856
2,927,295
2,927,2952,902,8561,383,624553,02086,616



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-578,825
Operating Income-578,825-578,825
 
Operating Expense (+$)
Research Development444,506
Selling General Administrative134,319
Selling And Marketing Expenses-
Operating Expense578,825578,825
 
Net Interest Income (+$)
Interest Income44,937
Interest Expense-6,441
Other Finance Cost-0
Net Interest Income38,496
 
Pretax Income (+$)
Operating Income-578,825
Net Interest Income38,496
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-496,920-622,234
EBIT - interestExpense = -6,441
-496,981
-490,540
Interest Expense6,441
Earnings Before Interest and Taxes (EBIT)--490,479
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-496,920
Tax Provision-61
Net Income From Continuing Ops-496,981-496,981
Net Income-496,981
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net43,409-38,496
 

Technical Analysis of Gracell Biotechnologies Inc.
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Gracell Biotechnologies Inc.. The general trend of Gracell Biotechnologies Inc. is BULLISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Gracell Biotechnologies Inc.'s overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (100.0%) Bearish trend (-100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Gracell Biotechnologies Inc..

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 10.44.

The bearish price targets are: 10.20 > 9.94 > 6.99.

Tweet this
Gracell Biotechnologies Inc. Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Gracell Biotechnologies Inc.. The current mas is .

The long score for the Moving Averages is 14/14.
The longshort score for the Moving Averages is 14/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Gracell Biotechnologies Inc. Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Gracell Biotechnologies Inc.. The current macd is 0.25668248.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Gracell Biotechnologies Inc. price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Gracell Biotechnologies Inc.. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Gracell Biotechnologies Inc. price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Gracell Biotechnologies Inc. Daily Moving Average Convergence/Divergence (MACD) ChartGracell Biotechnologies Inc. Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Gracell Biotechnologies Inc.. The current adx is 55.81.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Gracell Biotechnologies Inc. shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Gracell Biotechnologies Inc. Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Gracell Biotechnologies Inc.. The current sar is 10.39.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Gracell Biotechnologies Inc. Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Gracell Biotechnologies Inc.. The current rsi is 68.18. The current phase is Continuation in bull market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Continuation in bull market: Uptrend continues after a consolidation or pullback. Hold or add to existing positions.
Gracell Biotechnologies Inc. Daily Relative Strength Index (RSI) ChartGracell Biotechnologies Inc. Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Gracell Biotechnologies Inc.. The current phase is Correction in bull market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Gracell Biotechnologies Inc. price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Gracell Biotechnologies Inc. Daily Stochastic Oscillator ChartGracell Biotechnologies Inc. Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Gracell Biotechnologies Inc.. The current cci is 51.64.

Gracell Biotechnologies Inc. Daily Commodity Channel Index (CCI) ChartGracell Biotechnologies Inc. Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Gracell Biotechnologies Inc.. The current cmo is 18.75.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Gracell Biotechnologies Inc. Daily Chande Momentum Oscillator (CMO) ChartGracell Biotechnologies Inc. Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Gracell Biotechnologies Inc.. The current willr is -53.62318841.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Gracell Biotechnologies Inc. is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Gracell Biotechnologies Inc. Daily Williams %R ChartGracell Biotechnologies Inc. Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Gracell Biotechnologies Inc..

Gracell Biotechnologies Inc. Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Gracell Biotechnologies Inc.. The current atr is 0.145072.

Gracell Biotechnologies Inc. Daily Average True Range (ATR) ChartGracell Biotechnologies Inc. Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Gracell Biotechnologies Inc.. The current obv is 32,017,609.

Gracell Biotechnologies Inc. Daily On-Balance Volume (OBV) ChartGracell Biotechnologies Inc. Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Gracell Biotechnologies Inc.. The current mfi is 69.67.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Gracell Biotechnologies Inc. Daily Money Flow Index (MFI) ChartGracell Biotechnologies Inc. Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Gracell Biotechnologies Inc..

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-10-02SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-10-05MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-10-06MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-10-09MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-10-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-10-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-10-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-10-13CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-10-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-10-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-10-20WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-10-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-10-24STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2023-10-26BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-10-27STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-10-31STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-01BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-02STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-09STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-10STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-13STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-17SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-11-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-20STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-22RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-01-31STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-02-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Gracell Biotechnologies Inc. Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Gracell Biotechnologies Inc. based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5068.183
Ma 20Greater thanMa 5010.215
Ma 50Greater thanMa 1009.232
Ma 100Greater thanMa 2006.537
OpenGreater thanClose10.250
Total4/5 (80.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Gracell Biotechnologies Inc. with someone you think should read this too:
  • Are you bullish or bearish on Gracell Biotechnologies Inc.? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Gracell Biotechnologies Inc.? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Gracell Biotechnologies Inc.

I send you an email if I find something interesting about Gracell Biotechnologies Inc..


Comments

How you think about this?

Leave a comment

Stay informed about Gracell Biotechnologies Inc..

Receive notifications about Gracell Biotechnologies Inc. in your mailbox!